ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 6, 2021

8:30AM-10:30AM: Abstract Number: 0252

Role of Clinical and Laboratory Parameters in Differentiating Infection from Disease Flare in Febrile Patients of Systemic Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)

8:30AM-10:30AM: Abstract Number: 0397

Safety and Persistence of Monthly Intravenous Iloprost in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

8:30AM-10:30AM: Abstract Number: 0187

Safety and Tolerability of Nintedanib in Patients with Autoimmune Disease-Related Interstitial Lung Diseases: Pooled Data from the SENSCIS and INBUILD Trials

Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)

8:30AM-10:30AM: Abstract Number: 0100

Safety of COVID-19 Vaccines After First Vaccination in Patients with Rheumatic Diseases in a Patient Reported Survey

Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

8:30AM-10:30AM: Abstract Number: 0300

Salivary Gland Epithelial Cells Transcriptomic Analysis Highlight Their Potential Involvement in Extracellular Matrix Modification in Sjögren’s Syndrome

Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

8:30AM-10:30AM: Abstract Number: 0002

Salivary Sodium Levels in the Parotid Salivary Gland of SS Patients Suggest B-cell Mediated Epithelial Sodium Channel Disruption

B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)

8:30AM-10:30AM: Abstract Number: 0086

SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review

Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

8:30AM-10:30AM: Abstract Number: 0089

SARS-CoV-2 Seroprevalence and Seroconversion in a Systemic Lupus Erythematosus Cohort and Comparison to General Population Controls

Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

8:30AM-10:30AM: Abstract Number: 0373

Self-monitoring of Disease Activity with a Smartphone App Is Feasible in Routine Clinical Management of Patients with Axial Spondyloarthritis – a Proof of Concept Study

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)

8:30AM-10:30AM: Abstract Number: 0237

Self-perceived General Health at Start of Anti-TNF Therapy Predicts Therapeutic Response in Patients with Rheumatoid Arthritis: Analysis from the Czech Biologics Registry ATTRA

Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)

8:30AM-10:30AM: Abstract Number: 0371

Self-referral Strategy for Early Diagnosis of Axial Spondyloarthritis- Preliminary Analysis from Finding Axial Spondyloarthritis Study

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)

8:30AM-10:30AM: Abstract Number: 0176

Semi-quantitative Chest Computed Tomography (CT) Analysis in Pediatric Rheumatologic (PR) Patients with Diffuse Lung Disease

Imaging of Rheumatic Diseases Poster (0149–0182)

8:30AM-10:30AM: Abstract Number: 0321

Sequential Administration of Belimumab and Rituximab in Primary Sjögren’s Syndrome Reduces Minor Salivary Gland–Resident B Cells and Delays B-Cell Repopulation in Circulation

Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

8:30AM-10:30AM: Abstract Number: 0330

Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0338

Serum and Urine Galectin-9, IP-10 and SIGLEC-1 as Biomarkers of Disease Activity in Patients with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].